Original Article

Management Of Overactive Bladder Syndrome Efficacy Of New Pharmacological Agents.

Sara Gul[1],Sidra Gohar[2] , Kokab Saba[3] , Amina Bibi[4], Shadab Mumtaz[5]

[1,2,3,4,5] Department Of Obstetrics & Gynecology District Head Quarter Teaching Hospital Swabi

Corresponding Author : Amina Bibi
Email: aminashah0918@gmail.com
https://orcid.org/0000-0001-9216-1159

Received: 26-Sep-2024
Accepted: 26–Nov-2024
Online 05-Jan- 2025

ABSTRACT

Background: Overactive Bladder Syndrome (OAB) affects millions worldwide, causing frequent and urgent urination with or without incontinence. It disrupts daily life and poses a significant healthcare challenge. Advancements in pharmacological treatments have introduced innovative therapies that aim to improve bladder control and patient outcomes, offering hope for enhanced management.

Objectives: This study evaluates the efficacy and safety of new pharmacological agents for OAB, focusing on symptom reduction and patient quality of life improvement.

Study Design: A Randomized Controlled Trial (**RCT)**

Methods: A total of 150 patients diagnosed with OAB participated in a randomized, controlled trial. Participants received either beta-3 adrenergic receptor agonists, selective anticholinergic, or combination therapies for 12 weeks. Symptom changes were assessed using validated questionnaires, while safety was monitored through adverse event reporting. Statistical analysis included standard deviation and p-values to determine treatment efficacy and significance.

Results: Of the 150 patients, 80 received beta-3 adrenergic receptor agonists, 40 received selective anticholinergics, and 30 received combination therapy. Beta-3 adrenergic receptor agonists reduced urgency episodes by 45% (SD = 5.2, $p < 0.05$). Combination therapy showed the highest improvement, with a 60% reduction in symptoms (SD = 4.8, $p < 0.01$). Selective anticholinergics were effective but showed a higher incidence of side effects.

Conclusion: New pharmacological agents significantly improve OAB symptoms, with combination therapy offering the most substantial benefit. Beta-3 adrenergic receptor agonists demonstrate excellent efficacy and tolerability, marking a milestone in OA management. Further studies are recommended to refine treatment protocols and explore emerging therapies.

Keywords: Overactive Bladder, Pharmacological Agents, Beta-3 Agonists, Combination Therapy

How to Cite This Article:
Gul S, Gohar S, Saba K, Bibi A, Mumtaz S. Management of overactive bladder syndrome: Efficacy of new pharmacological agents. J Nowshera Med Coll. 2025;1(1):72-77. Available from: https://doi.org/10.69837/jnmc.v1i01.39.

Introduction

Overactive Bladder Syndrome (OAB) is a complex urological condition characterized by symptoms of urgency, frequency, nocturia, and urinary incontinence, affecting approximately 16% of the global population (1, 2). The syndrome disproportionately impacts older adults and women, contributing to significant physical discomfort and psychological distress (3, 4). While lifestyle interventions and bladder training have long been considered first-line treatments, their efficacy often proves insufficient, necessitating pharmacological solutions (5). Traditional anticholinergic agents, though effective, are limited by their side effect profile, including dry mouth, constipation, and cognitive dysfunction in elderly populations (6). Recent advancements in pharmacological research have introduced novel agents, including beta-3 adrenergic receptor agonists and combination therapies, which promise improved symptom management and reduced adverse effects (7, 8). Beta-3 agonists such as mirabegron offer a unique mechanism of action by relaxing the detrusor muscle during the bladder storage phase, increasing functional bladder capacity (9). Additionally, selective anticholinergics like solifenacin and fesoterodine have shown better tolerability due to their receptor specificity (10). This study aims to evaluate the efficacy and safety of these newer pharmacological agents, providing evidence-based insights for optimizing OAB treatment.

Methods

A total of 150 patients diagnosed with OAB participated in a randomized, controlled trial conducted over 12 weeks. Participants were stratified into three groups: beta-3 adrenergic receptor agonists (n=80), selective anticholinergics (n=40), and combination therapy (n=30). Symptom severity was assessed using validated tools, including the Overactive Bladder Symptom Score (OABSS) and Patient Perception of Bladder Condition (PPBC) questionnaires. Adverse events were recorded for safety evaluation. Statistical analyses were conducted using SPSS 24.0, employing ANOVA for group comparisons and paired t-tests for pre- and post-treatment assessments.

Data Collection

Data were collected through structured clinical interviews, patient-reported outcomes using standardized questionnaires, and bladder diaries maintained by participants over the study duration. Adherence was monitored through follow-up visits and digital reminders.

Statistical Analysis

Statistical analyses were performed using SPSS version 20.0. Descriptive statistics summarized baseline characteristics and outcome measures. ANOVA was used to compare treatment groups, while paired t-tests evaluated within-group changes. Statistical significance was set at $p < 0.05$.

Results

Among the 150 patients, beta-3 adrenergic receptor agonists led to a 45% reduction in urgency episodes (SD = 5.2, $p < 0.05$). Combination therapy demonstrated the highest efficacy, with a 60% improvement in OABSS scores (SD = 4.8, $p < 0.01$). Selective anticholinergics achieved moderate symptom relief but were associated with higher adverse event rates, including dry mouth (35%) and constipation (25%). The combination group

reported a notable improvement in nocturia frequency and overall quality of life.



Table 1: Patient Distribution

Parameter	Number
Total Patients	150
Beta-3 Agonists	80
Anticholinergics	40
Combination Therapy	30

Table 2: Symptom Reduction Statistics

Group	Mean Symptom Reduction (%)	Standard Deviation
Beta-3 Agonists	45	5.2
Anticholinergics	30	6.0
Combination Therapy	60	4.8

Table 3: Adverse Effects by Treatment Group

Adverse Effect	Beta-3 Agonists (%)	Anticholinergics (%)	Combination Therapy (%)
Dry Mouth	10	35	15
Constipation	5	25	10
Headache	8	15	10

Table 4: Key Outcomes by Treatment Group

Outcome	Beta-3 Agonists (%)	Combination Therapy (%)
Urgency Reduction	45	60
Frequency Reduction	50	70
Nocturia Improvement	40	55

Discussion

Recent findings from this study align with previous research, underscoring the efficacy of beta-3 adrenergic receptor agonists in managing OAB symptoms. For instance, a 2015 study by Nitti et al. demonstrated a 40% improvement in urgency episodes with mirabegron, comparable to the 45% reduction observed in this trial (11). Similarly, Chapple et al. (2016) highlighted the tolerability of mirabegron, with lower incidences of dry mouth and constipation compared to traditional anticholinergics, which aligns with our findings (12). Combination therapy has emerged as a superior option for symptom relief. Hashim et al. (2017) reported a 55% reduction in OAB symptoms with combined solifenacin and mirabegron therapy, closely mirroring the 60% reduction noted in this study (13). This synergy likely results from addressing both storage and voiding dysfunctions, making it a promising strategy for refractory cases. In contrast, selective anticholinergics showed moderate efficacy but higher side effect profiles. A 2018 meta-analysis by Freeman et al. confirmed the limitations of

these agents, particularly in older populations, due to cognitive side effects and gastrointestinal discomfort (14). Our study corroborates these findings, noting a 25% incidence of constipation with anticholinergic use. Emerging therapies like P2X3 receptor antagonists and botulinum toxin-A have also been explored. A 2019 trial by Smith et al. suggested that P2X3 antagonists could significantly reduce urgency and frequency, though long-term safety remains a concern (15). While not directly evaluated in this study, their potential inclusion in combination regimens warrants further research. This study's strengths include a well-powered sample size and comprehensive assessment tools, but its limitations, such as the short duration and lack of long-term follow-up, echo concerns raised by Herschorn et al. (2020) about the need for extended evaluations in OAB management (16). Future research should aim to incorporate real-world adherence data and explore the cost-effectiveness of these therapies (17).

Conclusion

The findings underscore the efficacy of newer pharmacological agents in managing OAB, with combination therapy offering superior outcomes. Beta-3 adrenergic receptor agonists are particularly effective, providing symptom relief with minimal side effects. This study highlights the need for individualized treatment approaches and further research into emerging therapies.

Limitations

This study was limited by its relatively short duration of 12 weeks, which may not capture the long-term efficacy and safety of the treatments. Additionally, real-world adherence data were not included, potentially affecting generalizability.

Future Directions

Future research should investigate the long-term effectiveness of these therapies, including their impact on quality of life over extended periods. Studies should also explore the integration of emerging agents like P2X3 receptor antagonists into combination regimens.

Abbreviations:

- **OAB** - Overactive Bladder
- **OABSS** - Overactive Bladder Symptom Score
- **PPBC** - Patient Perception of Bladder Condition
- **SD** - Standard Deviation
- **ANOVA** - Analysis of Variance
- **SPSS** - Statistical Package for the Social Sciences
- **P2X3** - Purinergic Receptor P2X Ligand-Gated Ion Channel 3
- **CNS** - Central Nervous System

Acknowledgement: We would like to thank the hospitals administration and everyone who helped us complete this study.

Disclaimer: Nil

Conflict of Interest: There is no conflict of interest.

Funding Disclosure: Nil

Authors Contribution

Concept & Design of Study: **Sara Gul**[1]
Drafting: **Sidra Gohar**[2]
Data Analysis:**Kokab Saba**[3] **, Amina Bibi**[4]
Critical Review: **, Shadab Mumtaz**[5]

Final Approval of version: **All Authors as mentioned above.**

References

1. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology in lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Urology. 2003;61(1):37-49.
2. Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms in the USA: Results from the EPIC study. BJU Int. 2004;92(4):409-414.
3. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5-26.
4. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol. 2006;50(6):1306-1314.
5. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: A systematic review and meta-analysis. Eur Urol. 2008;54(3):543-562.
6. Dmochowski RR, Rosenberg MT. Urologic complications of diabetes mellitus: Diabetic cystopathy. Am J Obstet Gynecol. 2002;187(3):S53-S58.
7. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta-3 agonist, in patients with overactive bladder: Results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283-295.
8. Yoshida M, Takeda M. The afferent pathway and the bladder: Possible therapeutic target for OAB. Int J Urol. 2014;21(8):673-679.
9. Wagg A, Dale M, Tretter R, et al. Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of mirabegron in older adults with overactive bladder. Age Ageing. 2014;43(5):666-673.
10. Andersson KE, Pehrson R. CNS involvement in overactive bladder. Nat Rev Urol. 2011;8(11):587-595.
11. Nitti VW, Herschorn S, Brucker BM, et al. Results of a phase III study of mirabegron in patients with OAB. Urology. 2015;85(3):535-540.

12. Chapple CR, Kaplan SA, Mitcheson D, et al. Mirabegron long-term safety study. Eur Urol. 2016;70(4):564-572.

13. Hashim H, Abrams P. Combination therapy for overactive bladder. Int J Clin Pract. 2017;71(5):e12999.

14. Freeman R, Hill S, Millard R, et al. Anticholinergics for overactive bladder in the elderly: A meta-analysis. J Urol. 2018;199(6):1376-1383.

15. Smith AB, Burgio KL, Goode PS. Emerging therapies for OAB: P2X3 antagonists. J Urol. 2019;201(2):456-464.

16. Herschorn S, Gajewski J, Schulz J, et al. Long-term safety and efficacy of combination OAB therapy. Can Urol Assoc J. 2020;14(2):E57-E64.

17. Abrams P, Wein AJ, van Kerrebroeck P, et al. Cost-effectiveness of OAB treatments: A systematic review. BJU Int. 2021;128(3):325-334.